ArticleBiological procedures online2026
Ethnopharmacological evaluation and metabolic mechanism of Sanjie Xiaoliu Granule in breast cancer with depression.
Article in Biological procedures online, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSanjie Xiaoliu Granule (SJXLG), a traditional multi-herbal prescription widely used in Chinese medicine, has been historically applied to "disperse nodules, soothe the liver, and relieve depression." It is clinically prescribed for patients with breast lumps, emotional stagnation, and cancer-related depression. However, the pharmacological basis underlying its dual anticancer and antidepressant effects remains poorly understood.This study aimed to evaluate the therapeutic efficacy and elucidate the molecular and metabolic mechanisms of SJXLG in breast cancer with depression (BCD) through integrated experimental and bioinformatics approaches. In vivo and in vitro BCD models were established to assess tumor growth, behavioral performance, and inflammatory cytokine levels. Liquid chromatography-mass spectrometry (LC-MS) identified active constituents of SJXLG. Bioinformatics analyses were used to screen key genes and signaling pathways, followed by validation via qRT-PCR and Western blot. Untargeted metabolomics was applied to explore the metabolic alterations in tumor tissues after SJXLG intervention.
resultsSJXLG significantly inhibited breast cancer cell proliferation, migration, and invasion, and improved depressive-like behaviors in tumor-bearing mice. The formula upregulated MAOA, LTF, PTGER3, and IGFBP6 expression and regulated multiple signaling pathways, including PPAR, AMPK, and PI3K-Akt/mTOR, which are involved in lipid metabolism, inflammation, and neurotransmitter synthesis. Untargeted metabolomics further revealed that SJXLG restored metabolic homeostasis by modulating lipid, amino acid, and energy metabolism, alleviating oxidative stress, and rebalancing neurotransmitter-related metabolites. These findings suggest that SJXLG exerts integrative effects through multi-target, multi-pathway regulation.
conclusionsSJXLG demonstrates a synergistic anticancer and antidepressant effect through the modulation of metabolic and signaling networks associated with inflammation, oxidative stress, and neurotransmission. These results provide experimental evidence for its ethnopharmacological application in managing body-mind comorbidities such as breast cancer with depression and highlight its potential as a safe and effective adjunct therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.